Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav - Delavirdine - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-11-03 11:26:24 Intel Viiv Integrase inhibitors Organofluorides Pfizer Biology Pharmacology Dolutegravir Shionogi Pharmaceutical industry Pharmaceutical sciences ViiV Healthcare GlaxoSmithKline		Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 94,97 KB Share Document on Facebook

	InsFtute of Molecular Systems Biology   Accelerating 3D Protein Modeling Using Cloud Computing   Lars Malmström, Ruedi Aebersold – ETH Zürich, IMSB h?p://www.imsb.ethz.ch  Wibke Sud DocID: 1xW13 - View Document
	Biology 7-12 "DBEFNJD.BQ Post-Baccalaureate DocID: 1xVVF - View Document
	Biology 7-12, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xVB1 - View Document
	北京大学基础医学院院长论坛报告题目： How to Publish High Quality Articles 报告人： Mirella Bucci, Ph.D. Senior Editor of Nature Chemical Biology 时 DocID: 1xVbh - View Document
	Group Henzinger Software Systems Theory Systems Biology Group members DocID: 1xV3x - View Document